Clivatuzumab is a humanized anti-myxinomab, which can target the MUC1 epitope highly expressed on the surface of most pancreatic cancer cells, and has a good therapeutic effect on a variety of tumor cells.
CAS Number:
[1622075-09-5]
* VAT and and shipping costs not included. Errors and price changes excepted
